Search

Your search keyword '"Jacobsohn L"' showing total 200 results
Start Over Author "Jacobsohn L"
200 results on '"Jacobsohn L"'

2. Impact of Risk Factors on COVID-19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID-19 Global Rheumatology Alliance Registry

Author

Yazdany, J, Ware, A, Wallace, Z, Bhana, S, Grainger, R, Hachulla, E, Richez, C, Cacoub, P, Hausmann, J, Liew, J, Sirotich, E, Jacobsohn, L, Strangfeld, A, Mateus, E, Hyrich, K, Gossec, L, Carmona, L, Lawson-Tovey, S, Kearsley-Fleet, L, Schaefer, M, Ribeiro, S, Al-Emadi, S, Hasseli, R, Müller-Ladner, U, Specker, C, Schulze-Koops, H, Bernardes, M, Fraga, V, Rodrigues, A, Sparks, J, Ljung, L, Di Giuseppe, D, Tidblad, L, Wise, L, Duarte-García, A, Ugarte-Gil, M, Colunga-Pedraza, I, Martínez-Martínez, M, Alpizar-Rodriguez, D, Xavier, R, Isnardi, C, Pera, M, Pons-Estel, G, Izadi, Z, Gianfrancesco, M, Carrara, G, Scirè, C, Zanetti, A, Machado, P, Wallace, ZS, Hausmann, JS, Liew, JW, Mateus, EF, Hyrich, KL, Ribeiro, SLE, Fraga, VM, Rodrigues, AM, Sparks, JA, Ugarte-Gil, MF, Colunga-Pedraza, IJ, Martínez-Martínez, MU, Xavier, RM, Isnardi, CA, Gianfrancesco, MA, Scirè, CA, Machado, PM, Yazdany, J, Ware, A, Wallace, Z, Bhana, S, Grainger, R, Hachulla, E, Richez, C, Cacoub, P, Hausmann, J, Liew, J, Sirotich, E, Jacobsohn, L, Strangfeld, A, Mateus, E, Hyrich, K, Gossec, L, Carmona, L, Lawson-Tovey, S, Kearsley-Fleet, L, Schaefer, M, Ribeiro, S, Al-Emadi, S, Hasseli, R, Müller-Ladner, U, Specker, C, Schulze-Koops, H, Bernardes, M, Fraga, V, Rodrigues, A, Sparks, J, Ljung, L, Di Giuseppe, D, Tidblad, L, Wise, L, Duarte-García, A, Ugarte-Gil, M, Colunga-Pedraza, I, Martínez-Martínez, M, Alpizar-Rodriguez, D, Xavier, R, Isnardi, C, Pera, M, Pons-Estel, G, Izadi, Z, Gianfrancesco, M, Carrara, G, Scirè, C, Zanetti, A, Machado, P, Wallace, ZS, Hausmann, JS, Liew, JW, Mateus, EF, Hyrich, KL, Ribeiro, SLE, Fraga, VM, Rodrigues, AM, Sparks, JA, Ugarte-Gil, MF, Colunga-Pedraza, IJ, Martínez-Martínez, MU, Xavier, RM, Isnardi, CA, Gianfrancesco, MA, Scirè, CA, and Machado, PM

Abstract

Objective: Approximately one third of individuals worldwide have not received a COVID-19 vaccine. Although studies have investigated risk factors linked to severe COVID-19 among unvaccinated people with rheumatic diseases (RDs), we know less about whether these factors changed as the pandemic progressed. We aimed to identify risk factors associated with severe COVID-19 in unvaccinated individuals in different pandemic epochs corresponding to major variants of concern. Methods: Patients with RDs and COVID-19 were entered into the COVID-19 Global Rheumatology Alliance Registry between March 2020 and June 2022. An ordinal logistic regression model (not hospitalized, hospitalized, and death) was used with date of COVID-19 diagnosis, age, sex, race and/or ethnicity, comorbidities, RD activity, medications, and the human development index (HDI) as covariates. The main analysis included all unvaccinated patients across COVID-19 pandemic epochs; subanalyses stratified patients according to RD types. Results: Among 19,256 unvaccinated people with RDs and COVID-19, those who were older, male, had more comorbidities, used glucocorticoids, had higher disease activity, or lived in lower HDI regions had worse outcomes across epochs. For those with rheumatoid arthritis, sulfasalazine and B-cell–depleting therapy were associated with worse outcomes, and tumor necrosis factor inhibitors were associated with improved outcomes. In those with connective tissue disease or vasculitis, B-cell–depleting therapy was associated with worse outcomes. Conclusion: Risk factors for severe COVID-19 outcomes were similar throughout pandemic epochs in unvaccinated people with RDs. Ongoing efforts, including vaccination, are needed to reduce COVID-19 severity in this population, particularly in those with medical and social vulnerabilities identified in this study.

Published
2024

4. Risk of severe COVID-19 associated with immune-modifying drugs: Data from PsoProtect and Global Rheumatology Alliance registries.

Author

Mahil, S, Schaefer, M, Dand, N, Yiu, Z, Hyrich, K, Strangfeld, A, Yates, M, Carmona, L, Gossec, L, Mateus, E, Lawson-Tovey, S, Wiek, D, Jacobsohn, L, Isnardi, C, Quintana, R, Soriano, E, Wallace, Z, Bhana, S, Gore-Massey, M, Grainger, R, Hausmann, J, Liew, J, Sirotich, E, Mason, K, Tsakok, T, Meynell, F, Coker, B, Vincent, A, Urmston, D, Mcateer, H, Vesty, A, Kelly, J, Lancelot, C, Moorhead, L, Mackenzie, T, Rossi, M, Rivera, R, Mahe, E, Carugno, A, Magnano, M, Rech, G, Balogh, E, Feldman, S, De La Cruz, C, Di Meglio, P, Contreras, C, Choon, S, Capon, F, Torres, T, Naldi, L, Weinman, J, Brown, M, Galloway, J, Norton, S, Lambert, J, Spuls, P, Van Huizen, A, Jullien, D, Bachelez, H, Mcmahon, D, Freeman, E, Gisondi, P, Puig, L, Warren, R, Langan, S, Sufka, P, Robinson, P, Yazdany, J, Griffiths, C, Barker, J, Machado, P, Smith, C, Mahil SK, Schaefer M, Dand N, Yiu ZZN, Hyrich KL, Strangfeld A, Yates M, Carmona L, Gossec L, Mateus EF, Lawson-Tovey S, Wiek D, Jacobsohn L, Isnardi CA, Quintana R, Soriano ER, Wallace ZS, Bhana S, Gore-Massey M, Grainger R, Hausmann JS, Liew JW, Sirotich E, Mason KJ, Tsakok T, Meynell F, Coker B, Vincent A, Urmston D, McAteer H, Vesty A, Kelly J, Lancelot C, Moorhead L, Mackenzie T, Rossi MT, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh EA, Feldman SR, De La Cruz C, Di Meglio P, Contreras CR, Choon SE, Capon F, Torres T, Naldi L, Weinman J, Brown MA, Galloway JB, Norton S, Lambert J, Spuls P, Van Huizen AM, Jullien D, Bachelez H, McMahon DE, Freeman EE, Gisondi P, Puig L, Warren RB, Langan SM, Sufka P, Robinson PC, Yazdany J, Griffiths CEM, Barker JN, Machado PM, Smith CH., Mahil, S, Schaefer, M, Dand, N, Yiu, Z, Hyrich, K, Strangfeld, A, Yates, M, Carmona, L, Gossec, L, Mateus, E, Lawson-Tovey, S, Wiek, D, Jacobsohn, L, Isnardi, C, Quintana, R, Soriano, E, Wallace, Z, Bhana, S, Gore-Massey, M, Grainger, R, Hausmann, J, Liew, J, Sirotich, E, Mason, K, Tsakok, T, Meynell, F, Coker, B, Vincent, A, Urmston, D, Mcateer, H, Vesty, A, Kelly, J, Lancelot, C, Moorhead, L, Mackenzie, T, Rossi, M, Rivera, R, Mahe, E, Carugno, A, Magnano, M, Rech, G, Balogh, E, Feldman, S, De La Cruz, C, Di Meglio, P, Contreras, C, Choon, S, Capon, F, Torres, T, Naldi, L, Weinman, J, Brown, M, Galloway, J, Norton, S, Lambert, J, Spuls, P, Van Huizen, A, Jullien, D, Bachelez, H, Mcmahon, D, Freeman, E, Gisondi, P, Puig, L, Warren, R, Langan, S, Sufka, P, Robinson, P, Yazdany, J, Griffiths, C, Barker, J, Machado, P, Smith, C, Mahil SK, Schaefer M, Dand N, Yiu ZZN, Hyrich KL, Strangfeld A, Yates M, Carmona L, Gossec L, Mateus EF, Lawson-Tovey S, Wiek D, Jacobsohn L, Isnardi CA, Quintana R, Soriano ER, Wallace ZS, Bhana S, Gore-Massey M, Grainger R, Hausmann JS, Liew JW, Sirotich E, Mason KJ, Tsakok T, Meynell F, Coker B, Vincent A, Urmston D, McAteer H, Vesty A, Kelly J, Lancelot C, Moorhead L, Mackenzie T, Rossi MT, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh EA, Feldman SR, De La Cruz C, Di Meglio P, Contreras CR, Choon SE, Capon F, Torres T, Naldi L, Weinman J, Brown MA, Galloway JB, Norton S, Lambert J, Spuls P, Van Huizen AM, Jullien D, Bachelez H, McMahon DE, Freeman EE, Gisondi P, Puig L, Warren RB, Langan SM, Sufka P, Robinson PC, Yazdany J, Griffiths CEM, Barker JN, Machado PM, and Smith CH.

Published
2022

5. Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Author

Yeoh, S, Gianfrancesco, M, Lawson-Tovey, S, Hyrich, K, Strangfeld, A, Gossec, L, Carmona, L, Mateus, E, Schafer, M, Richez, C, Hachulla, E, Holmqvist, M, Scire, C, Lorenz, H, Voll, R, Hasseli, R, Jayatilleke, A, Hsu, T, D'Silva, K, Pimentel-Quiroz, V, Vasquez Del Mercado, M, Shinjo, S, Neto, E, Junior, L, De Oliveira E Silva Montandon, A, Pons-Estel, G, Ornella, S, D'Angelo Exeni, M, Velozo, E, Jordan, P, Sirotich, E, Hausmann, J, Liew, J, Jacobsohn, L, Gore-Massy, M, Sufka, P, Grainger, R, Bhana, S, Wallace, Z, Robinson, P, Yazdany, J, Machado, P, Yeoh S. -A., Gianfrancesco M., Lawson-Tovey S., Hyrich K. L., Strangfeld A., Gossec L., Carmona L., Mateus E. F., Schafer M., Richez C., Hachulla E., Holmqvist M., Scire C. A., Lorenz H. -M., Voll R. E., Hasseli R., Jayatilleke A., Hsu T. Y. -T., D'Silva K. M., Pimentel-Quiroz V. R., Vasquez Del Mercado M., Shinjo S. K., Neto E. T. D. R., Junior L. F. D. R., De Oliveira E Silva Montandon A. C., Pons-Estel G. J., Ornella S., D'Angelo Exeni M. E., Velozo E., Jordan P., Sirotich E., Hausmann J. S., Liew J. W., Jacobsohn L., Gore-Massy M., Sufka P., Grainger R., Bhana S., Wallace Z., Robinson P. C., Yazdany J., MacHado P. M., Yeoh, S, Gianfrancesco, M, Lawson-Tovey, S, Hyrich, K, Strangfeld, A, Gossec, L, Carmona, L, Mateus, E, Schafer, M, Richez, C, Hachulla, E, Holmqvist, M, Scire, C, Lorenz, H, Voll, R, Hasseli, R, Jayatilleke, A, Hsu, T, D'Silva, K, Pimentel-Quiroz, V, Vasquez Del Mercado, M, Shinjo, S, Neto, E, Junior, L, De Oliveira E Silva Montandon, A, Pons-Estel, G, Ornella, S, D'Angelo Exeni, M, Velozo, E, Jordan, P, Sirotich, E, Hausmann, J, Liew, J, Jacobsohn, L, Gore-Massy, M, Sufka, P, Grainger, R, Bhana, S, Wallace, Z, Robinson, P, Yazdany, J, Machado, P, Yeoh S. -A., Gianfrancesco M., Lawson-Tovey S., Hyrich K. L., Strangfeld A., Gossec L., Carmona L., Mateus E. F., Schafer M., Richez C., Hachulla E., Holmqvist M., Scire C. A., Lorenz H. -M., Voll R. E., Hasseli R., Jayatilleke A., Hsu T. Y. -T., D'Silva K. M., Pimentel-Quiroz V. R., Vasquez Del Mercado M., Shinjo S. K., Neto E. T. D. R., Junior L. F. D. R., De Oliveira E Silva Montandon A. C., Pons-Estel G. J., Ornella S., D'Angelo Exeni M. E., Velozo E., Jordan P., Sirotich E., Hausmann J. S., Liew J. W., Jacobsohn L., Gore-Massy M., Sufka P., Grainger R., Bhana S., Wallace Z., Robinson P. C., Yazdany J., and MacHado P. M.

Abstract

Objectives To investigate factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy (IIM). Methods Demographic data, clinical characteristics and COVID-19 outcome severity of adults with IIM were obtained from the COVID-19 Global Rheumatology Alliance physician-reported registry. A 3-point ordinal COVID-19 severity scale was defined: (1) no hospitalisation, (2) hospitalisation (and no death) and (3) death. ORs were estimated using multivariable ordinal logistic regression. Sensitivity analyses were performed using a 4-point ordinal scale: (1) no hospitalisation, (2) hospitalisation with no oxygen (and no death), (3) hospitalisation with oxygen/ventilation (and no death) and 4) death. Results Of 348 patients, 48% were not hospitalised, 39% were hospitalised (and did not die) and 13% died. Older age (OR=1.59/decade, 95% CI 1.31 to 1.91), high disease activity (OR=3.50, 95% CI 1.25 to 9.83; vs remission), ≥2 comorbidities (OR=2.63, 95% CI 1.39 to 4.98; vs none), prednisolone-equivalent dose >7.5 mg/day (OR=2.40, 95% CI 1.09 to 5.28; vs no intake) and exposure to rituximab (OR=2.71, 95% CI 1.28 to 5.72; vs conventional synthetic disease-modifying antirheumatic drugs only) were independently associated with severe COVID-19. In addition to these variables, in the sensitivity analyses, male sex (OR range: 1.65-1.83; vs female) was also significantly associated with severe outcomes, while COVID-19 diagnosis after 1 October 2020 (OR range: 0.51-0.59; vs on/before 15 June 2020) was significantly associated with less severe outcomes, but these associations were not significant in the main model (OR=1.57, 95% CI 0.95 to 2.59; and OR=0.61, 95% CI 0.37 to 1.00; respectively). Conclusions This is the first large registry data on outcomes of COVID-19 in people with IIM. Older age, male sex, higher comorbidity burden, high disease activity, prednisolone-equivalent dose >7.5 mg/day and rituximab exposure were associated with severe COVID-19. These

Published
2022

7. Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Author

Strangfeld, A, Schafer, M, Gianfrancesco, M, Lawson-Tovey, S, Liew, J, Ljung, L, Mateus, E, Richez, C, Santos, M, Schmajuk, G, Scire, C, Sirotich, E, Sparks, J, Sufka, P, Thomas, T, Trupin, L, Wallace, Z, Al-Adely, S, Bachiller-Corral, J, Bhana, S, Cacoub, P, Carmona, L, Costello, R, Costello, W, Gossec, L, Grainger, R, Hachulla, E, Hasseli, R, Hausmann, J, Hyrich, K, Izadi, Z, Jacobsohn, L, Katz, P, Kearsley-Fleet, L, Robinson, P, Yazdany, J, Machado, P, Strangfeld A., Schafer M., Gianfrancesco M. A., Lawson-Tovey S., Liew J. W., Ljung L., Mateus E. F., Richez C., Santos M. J., Schmajuk G., Scire C. A., Sirotich E., Sparks J. A., Sufka P., Thomas T., Trupin L., Wallace Z. S., Al-Adely S., Bachiller-Corral J., Bhana S., Cacoub P., Carmona L., Costello R., Costello W., Gossec L., Grainger R., Hachulla E., Hasseli R., Hausmann J. S., Hyrich K. L., Izadi Z., Jacobsohn L., Katz P., Kearsley-Fleet L., Robinson P. C., Yazdany J., Machado P. M., Strangfeld, A, Schafer, M, Gianfrancesco, M, Lawson-Tovey, S, Liew, J, Ljung, L, Mateus, E, Richez, C, Santos, M, Schmajuk, G, Scire, C, Sirotich, E, Sparks, J, Sufka, P, Thomas, T, Trupin, L, Wallace, Z, Al-Adely, S, Bachiller-Corral, J, Bhana, S, Cacoub, P, Carmona, L, Costello, R, Costello, W, Gossec, L, Grainger, R, Hachulla, E, Hasseli, R, Hausmann, J, Hyrich, K, Izadi, Z, Jacobsohn, L, Katz, P, Kearsley-Fleet, L, Robinson, P, Yazdany, J, Machado, P, Strangfeld A., Schafer M., Gianfrancesco M. A., Lawson-Tovey S., Liew J. W., Ljung L., Mateus E. F., Richez C., Santos M. J., Schmajuk G., Scire C. A., Sirotich E., Sparks J. A., Sufka P., Thomas T., Trupin L., Wallace Z. S., Al-Adely S., Bachiller-Corral J., Bhana S., Cacoub P., Carmona L., Costello R., Costello W., Gossec L., Grainger R., Hachulla E., Hasseli R., Hausmann J. S., Hyrich K. L., Izadi Z., Jacobsohn L., Katz P., Kearsley-Fleet L., Robinson P. C., Yazdany J., and Machado P. M.

Abstract

Objectives To determine factors associated with COVID-19-related death in people with rheumatic diseases. Methods Physician-reported registry of adults with rheumatic disease and confirmed or presumptive COVID-19 (from 24 March to 1 July 2020). The primary outcome was COVID-19-related death. Age, sex, smoking status, comorbidities, rheumatic disease diagnosis, disease activity and medications were included as covariates in multivariable logistic regression models. Analyses were further stratified according to rheumatic disease category. Results Of 3729 patients (mean age 57 years, 68% female), 390 (10.5%) died. Independent factors associated with COVID-19-related death were age (66-75 years: OR 3.00, 95% CI 2.13 to 4.22; >75 years: 6.18, 4.47 to 8.53; both vs ≤65 years), male sex (1.46, 1.11 to 1.91), hypertension combined with cardiovascular disease (1.89, 1.31 to 2.73), chronic lung disease (1.68, 1.26 to 2.25) and prednisolone-equivalent dosage >10 mg/day (1.69, 1.18 to 2.41; vs no glucocorticoid intake). Moderate/high disease activity (vs remission/low disease activity) was associated with higher odds of death (1.87, 1.27 to 2.77). Rituximab (4.04, 2.32 to 7.03), sulfasalazine (3.60, 1.66 to 7.78), immunosuppressants (azathioprine, cyclophosphamide, ciclosporin, mycophenolate or tacrolimus: 2.22, 1.43 to 3.46) and not receiving any disease-modifying anti-rheumatic drug (DMARD) (2.11, 1.48 to 3.01) were associated with higher odds of death, compared with methotrexate monotherapy. Other synthetic/biological DMARDs were not associated with COVID-19-related death. Conclusion Among people with rheumatic disease, COVID-19-related death was associated with known general factors (older age, male sex and specific comorbidities) and disease-specific factors (disease activity and specific medications). The association with moderate/high disease activity highlights the importance of adequate disease control with DMARDs, preferably without increasing glucocorticoid dos

Published
2021

8. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

Author

Sparks, J, Wallace, Z, Seet, A, Gianfrancesco, M, Izadi, Z, Hyrich, K, Strangfeld, A, Gossec, L, Carmona, L, Mateus, E, Lawson-Tovey, S, Trupin, L, Rush, S, Katz, P, Schmajuk, G, Jacobsohn, L, Wise, L, Gilbert, E, Duarte-Garcia, A, Valenzuela-Almada, M, Pons-Estel, G, Isnardi, C, Berbotto, G, Hsu, T, D'Silva, K, Patel, N, Kearsley-Fleet, L, Schafer, M, Ribeiro, S, Al Emadi, S, Tidblad, L, Scire, C, Raffeiner, B, Thomas, T, Flipo, R, Avouac, J, Seror, R, Bernardes, M, Cunha, M, Hasseli, R, Schulze-Koops, H, Muller-Ladner, U, Specker, C, De Souza, V, Da Mota, L, Gomides, A, Dieude, P, Nikiphorou, E, Kronzer, V, Singh, N, Ugarte-Gil, M, Wallace, B, Akpabio, A, Thomas, R, Bhana, S, Costello, W, Grainger, R, Hausmann, J, Liew, J, Sirotich, E, Sufka, P, Robinson, P, Machado, P, Yazdany, J, Sparks J. A., Wallace Z. S., Seet A. M., Gianfrancesco M. A., Izadi Z., Hyrich K. L., Strangfeld A., Gossec L., Carmona L., Mateus E. F., Lawson-Tovey S., Trupin L., Rush S., Katz P., Schmajuk G., Jacobsohn L., Wise L., Gilbert E. L., Duarte-Garcia A., Valenzuela-Almada M. O., Pons-Estel G. J., Isnardi C. A., Berbotto G. A., Hsu T. Y. -T., D'Silva K. M., Patel N. J., Kearsley-Fleet L., Schafer M., Ribeiro S. L. E., Al Emadi S., Tidblad L., Scire C. A., Raffeiner B., Thomas T., Flipo R. -M., Avouac J., Seror R., Bernardes M., Cunha M. M., Hasseli R., Schulze-Koops H., Muller-Ladner U., Specker C., De Souza V. A., Da Mota L. M. H., Gomides A. P. M., Dieude P., Nikiphorou E., Kronzer V. L., Singh N., Ugarte-Gil M. F., Wallace B., Akpabio A., Thomas R., Bhana S., Costello W., Grainger R., Hausmann J. S., Liew J. W., Sirotich E., Sufka P., Robinson P. C., MacHado P. M., Yazdany J., Sparks, J, Wallace, Z, Seet, A, Gianfrancesco, M, Izadi, Z, Hyrich, K, Strangfeld, A, Gossec, L, Carmona, L, Mateus, E, Lawson-Tovey, S, Trupin, L, Rush, S, Katz, P, Schmajuk, G, Jacobsohn, L, Wise, L, Gilbert, E, Duarte-Garcia, A, Valenzuela-Almada, M, Pons-Estel, G, Isnardi, C, Berbotto, G, Hsu, T, D'Silva, K, Patel, N, Kearsley-Fleet, L, Schafer, M, Ribeiro, S, Al Emadi, S, Tidblad, L, Scire, C, Raffeiner, B, Thomas, T, Flipo, R, Avouac, J, Seror, R, Bernardes, M, Cunha, M, Hasseli, R, Schulze-Koops, H, Muller-Ladner, U, Specker, C, De Souza, V, Da Mota, L, Gomides, A, Dieude, P, Nikiphorou, E, Kronzer, V, Singh, N, Ugarte-Gil, M, Wallace, B, Akpabio, A, Thomas, R, Bhana, S, Costello, W, Grainger, R, Hausmann, J, Liew, J, Sirotich, E, Sufka, P, Robinson, P, Machado, P, Yazdany, J, Sparks J. A., Wallace Z. S., Seet A. M., Gianfrancesco M. A., Izadi Z., Hyrich K. L., Strangfeld A., Gossec L., Carmona L., Mateus E. F., Lawson-Tovey S., Trupin L., Rush S., Katz P., Schmajuk G., Jacobsohn L., Wise L., Gilbert E. L., Duarte-Garcia A., Valenzuela-Almada M. O., Pons-Estel G. J., Isnardi C. A., Berbotto G. A., Hsu T. Y. -T., D'Silva K. M., Patel N. J., Kearsley-Fleet L., Schafer M., Ribeiro S. L. E., Al Emadi S., Tidblad L., Scire C. A., Raffeiner B., Thomas T., Flipo R. -M., Avouac J., Seror R., Bernardes M., Cunha M. M., Hasseli R., Schulze-Koops H., Muller-Ladner U., Specker C., De Souza V. A., Da Mota L. M. H., Gomides A. P. M., Dieude P., Nikiphorou E., Kronzer V. L., Singh N., Ugarte-Gil M. F., Wallace B., Akpabio A., Thomas R., Bhana S., Costello W., Grainger R., Hausmann J. S., Liew J. W., Sirotich E., Sufka P., Robinson P. C., MacHado P. M., and Yazdany J.

Abstract

Objective To investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA). Methods We analysed the COVID-19 Global Rheumatology Alliance physician registry (from 24 March 2020 to 12 April 2021). We investigated b/tsDMARD use for RA at the clinical onset of COVID-19 (baseline): abatacept (ABA), rituximab (RTX), Janus kinase inhibitors (JAKi), interleukin 6 inhibitors (IL-6i) or tumour necrosis factor inhibitors (TNFi, reference group). The ordinal COVID-19 severity outcome was (1) no hospitalisation, (2) hospitalisation without oxygen, (3) hospitalisation with oxygen/ventilation or (4) death. We used ordinal logistic regression to estimate the OR (odds of being one level higher on the ordinal outcome) for each drug class compared with TNFi, adjusting for potential baseline confounders. Results Of 2869 people with RA (mean age 56.7 years, 80.8% female) on b/tsDMARD at the onset of COVID-19, there were 237 on ABA, 364 on RTX, 317 on IL-6i, 563 on JAKi and 1388 on TNFi. Overall, 613 (21%) were hospitalised and 157 (5.5%) died. RTX (OR 4.15, 95% CI 3.16 to 5.44) and JAKi (OR 2.06, 95% CI 1.60 to 2.65) were each associated with worse COVID-19 severity compared with TNFi. There were no associations between ABA or IL6i and COVID-19 severity. Conclusions People with RA treated with RTX or JAKi had worse COVID-19 severity than those on TNFi. The strong association of RTX and JAKi use with poor COVID-19 outcomes highlights prioritisation of risk mitigation strategies for these people.

Published
2021

9. Semiconducting and scintillating glasses for x-ray detection.

Author

Smith, B., Mucciaccio, J., Caplice, T., Wadle, L., McClanahan, L., Jacobsohn, L. G., and Akgun, U.

Subjects
X-ray detection, CADMIUM zinc telluride, MASS attenuation coefficients, ACTIVE medium, EXCITATION spectrum
Abstract

X-ray detectors are commonly used for medical, crystallography and space physics applications. Most of the current x-ray detectors use cadmium zinc telluride (CZT) as the active medium. This report investigates high density semiconducting and scintillating glasses as potential alternatives to CZT. For the semiconducting glasses, samples composed of xCuO– ((1−x)/2)PbO–((1−x)/2)V2O5 and xFeO–((1−x)/2)PbO–((1−x)/2)V2O5, for the scintillating glasses, samples composed of xGd2O3+yWO3+(1−x−y)2H3BO3, doped with 1–6% Eu3+ or Tb3+, were investigated in this study. The glass-making conditions, density, Raman spectroscopy analysis, photoluminescence excitation and emission spectra, as well as conductivity measurements performed on various samples, are reported. The interaction of x-rays with all the glass samples was simulated using GATE software, and their mass attenuation coefficients were calculated and compared with CZT. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

11. OP0249 CHARACTERISTICS ASSOCIATED WITH POOR COVID-19 OUTCOMES IN PEOPLE WITH PSORIASIS AND SPONDYLOARTHRITIS: DATA FROM THE COVID-19 PsoProtect AND GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRIES

Author

Machado, P. M., primary, Schaefer, M., additional, Mahil, S., additional, Dand, N., additional, Gianfrancesco, M., additional, Lawson-Tovey, S., additional, Yiu, Z., additional, Yates, M., additional, Hyrich, K., additional, Gossec, L., additional, Carmona, L., additional, Mateus, E., additional, Wiek, D., additional, Bhana, S., additional, Gore-Massy, M., additional, Grainger, R., additional, Hausmann, J., additional, Sufka, P., additional, Sirotich, E., additional, Wallace, Z., additional, Olofsson, T., additional, Lomater, C., additional, Romeo, N., additional, Wendling, D., additional, Pham, T., additional, Miceli Richard, C., additional, Fautrel, B., additional, Silva, L., additional, Santos, H., additional, Martins, F. R., additional, Hasseli, R., additional, Pfeil, A., additional, Regierer, A., additional, Isnardi, C., additional, Soriano, E., additional, Quintana, R., additional, Omura, F., additional, Machado Ribeiro, F., additional, Pinheiro, M., additional, Bautista-Molano, W., additional, Alpizar-Rodriguez, D., additional, Saad, C., additional, Dubreuil, M., additional, Haroon, N., additional, Gensler, L. S., additional, Dau, J., additional, Jacobsohn, L., additional, Liew, J., additional, Strangfeld, A., additional, Barker, J., additional, Griffiths, C. E. M., additional, Robinson, P., additional, Yazdany, J., additional, and Smith, C., additional

Published
2022
Full Text
View/download PDF

12. OP0252 FACTORS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHY: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRY

Author

Yeoh, S. A., primary, Gianfrancesco, M., additional, Lawson-Tovey, S., additional, Hyrich, K., additional, Strangfeld, A., additional, Gossec, L., additional, Carmona, L., additional, Mateus, E., additional, Schaefer, M., additional, Richez, C., additional, Hachulla, E., additional, Holmqvist, M., additional, Scirè, C. A., additional, Hasseli, R., additional, Jayatilleke, A., additional, Hsu, T., additional, D’Silva, K., additional, Pimentel-Quiroz, V., additional, Vasquez del Mercado, M., additional, Katsuyuki Shinjo, S., additional, Reis Neto, E., additional, Rocha, L., additional, Montandon, A. C. D. O. E. S., additional, Jordan, P., additional, Sirotich, E., additional, Hausmann, J., additional, Liew, J., additional, Jacobsohn, L., additional, Gore-Massy, M., additional, Sufka, P., additional, Grainger, R., additional, Bhana, S., additional, Wallace, Z., additional, Robinson, P., additional, Yazdany, J., additional, and Machado, P., additional

Published
2022
Full Text
View/download PDF

13. OP0286 CHARACTERISTICS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE (COVID-19 GRA)

Author

Ugarte-Gil, M. F., primary, Alarcon, G. S., additional, Seet, A., additional, Izadi, Z., additional, Reategui Sokolova, C., additional, Clarke, A. E., additional, Wise, L., additional, Pons-Estel, G., additional, Santos, M. J., additional, Bernatsky, S., additional, Mathias, L., additional, Lim, N., additional, Sparks, J., additional, Wallace, Z., additional, Hyrich, K., additional, Strangfeld, A., additional, Gossec, L., additional, Carmona, L., additional, Mateus, E., additional, Lawson-Tovey, S., additional, Trupin, L., additional, Rush, S., additional, Schmajuk, G., additional, Katz, P., additional, Jacobsohn, L., additional, Al Emadi, S., additional, Gilbert, E., additional, Duarte-Garcia, A., additional, Valenzuela-Almada, M., additional, Hsu, T., additional, D’silva, K., additional, Serling-Boyd, N., additional, Dieudé, P., additional, Nikiphorou, E., additional, Kronzer, V., additional, Singh, N., additional, Wallace, B., additional, Akpabio, A., additional, Thomas, R., additional, Bhana, S., additional, Costello, W., additional, Grainger, R., additional, Hausmann, J., additional, Liew, J., additional, Sirotich, E., additional, Sufka, P., additional, Robinson, P., additional, Machado, P., additional, Gianfrancesco, M., additional, and Yazdany, J., additional

Published
2021
Full Text
View/download PDF

14. OP0288 MACHINE LEARNING ALGORITHMS TO PREDICT COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME IN PATIENTS WITH RHEUMATIC DISEASES: RESULTS FROM THE GLOBAL RHEUMATOLOGY ALLIANCE PROVIDER REGISTRY

Author

Izadi, Z., primary, Gianfrancesco, M., additional, Hyrich, K., additional, Strangfeld, A., additional, Gossec, L., additional, Carmona, L., additional, Mateus, E., additional, Lawson-Tovey, S., additional, Trupin, L., additional, Rush, S., additional, Schmajuk, G., additional, Jacobsohn, L., additional, Katz, P., additional, Al Emadi, S., additional, Wise, L., additional, Gilbert, E., additional, Valenzuela-Almada, M., additional, Duarte-Garcia, A., additional, Sparks, J., additional, Hsu, T., additional, D’silva, K., additional, Serling-Boyd, N., additional, Bhana, S., additional, Costello, W., additional, Grainger, R., additional, Hausmann, J., additional, Liew, J., additional, Sirotich, E., additional, Sufka, P., additional, Wallace, Z., additional, Machado, P., additional, Robinson, P., additional, and Yazdany, J., additional

Published
2021
Full Text
View/download PDF

15. OP0006 ASSOCIATIONS OF BASELINE USE OF BIOLOGIC OR TARGETED SYNTHETIC DMARDS WITH COVID-19 SEVERITY IN RHEUMATOID ARTHRITIS: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE

Author

Sparks, J., primary, Wallace, Z., additional, Seet, A., additional, Gianfrancesco, M., additional, Izadi, Z., additional, Hyrich, K., additional, Strangfeld, A., additional, Gossec, L., additional, Carmona, L., additional, Mateus, E., additional, Lawson-Tovey, S., additional, Trupin, L., additional, Rush, S., additional, Schmajuk, G., additional, Katz, P., additional, Jacobsohn, L., additional, Al Emadi, S., additional, Wise, L., additional, Gilbert, E., additional, Duarte-Garcia, A., additional, Valenzuela-Almada, M., additional, Hsu, T., additional, D’silva, K., additional, Serling-Boyd, N., additional, Dieudé, P., additional, Nikiphorou, E., additional, Kronzer, V., additional, Singh, N., additional, Ugarte-Gil, M. F., additional, Wallace, B., additional, Akpabio, A., additional, Thomas, R., additional, Bhana, S., additional, Costello, W., additional, Grainger, R., additional, Hausmann, J., additional, Liew, J., additional, Sirotich, E., additional, Sufka, P., additional, Robinson, P., additional, Machado, P., additional, and Yazdany, J., additional

Published
2021
Full Text
View/download PDF

25. Synthesis, structure, and scintillation of Ce-doped gadolinium oxyorthosilicate nanoparticles prepared by solution combustion synthesis.

Author

Jacobsohn, L. G., Tornga, S. C., Blair, M. W., Bennett, B. L., Muenchausen, R. E., Wang, R., Crozier, P. A., and Cooke, D. W.

Subjects
*GADOLINIUM, *NANOPARTICLES, *SELF-propagating high-temperature synthesis, *SILICON oxide, *THERMOLUMINESCENCE
Abstract

The synthesis of Ce-doped Gd oxyorthosilicate nanoparticles using the solution combustion synthesis (SCS) method was investigated as a function of the amount of SiO2 in the precursor mixture. The SCS product consists of mixtures of Ce-doped Gd2SiO5, Gd4.67(SiO4)3O, and Gd2O3, whose relative concentrations depend on the amount of SiO2 in the precursor mixture; the synthesis of GSO:Ce was obtained with a reduction by 30% of the SiO2 content. Accordingly, this is the brightest material produced, with a photoluminescence signal that is comparable to that obtained from the bulk sample. Thermoluminescence (TL) results showed a considerably lower concentration of trapping defects in the nanoparticles than in the bulk sample. A previous study [E. G. Yukihara, L. G. Jacobsohn, M. W. Blair, B. L. Bennett, S. C. Tornga, and R. E. Muenchausen, J. Lumin. 130, 2309-2316 (2010)] reporting a comparison between photoluminescence and scintillation measurements, coupled to the TL characterization, suggests that surfaces play a major role in decreasing the scintillation efficiency of the nanoparticles. These results show that it is possible to prepare relatively bright scintillator powders using the SCS method. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

26. Y2O3:Bi nanophosphor: Solution combustion synthesis, structure, and luminescence.

Author

Jacobsohn, L. G., Blair, M. W., Tornga, S. C., Brown, L. O., Bennett, B. L., and Muenchausen, R. E.

Subjects
*NANOSTRUCTURED materials, *PHOSPHORS, *COMBUSTION, *LUMINESCENCE, *PHOTOLUMINESCENCE, *THERMOLUMINESCENCE, *GLYCINE
Abstract

Photoluminescence (PL), radioluminescence (RL), and thermoluminescence (TL) investigation of Y2O3:Bi nanophosphors prepared by solution combustion synthesis using urea, glycine, and hexamethylenetetramine (HMT) as fuels was carried out. The as-prepared nanopowders have increasing crystallinity and average crystallite sizes for urea, glycine, and HMT, respectively. Luminescence is composed of two emission bands centered at 408 and 505 nm due to two nonequivalent Bi3+ sites with symmetry S6 and C2, respectively. The occupancy of these sites depends on the synthesis conditions, in agreement with theoretical predictions. Annealing at 1000 °C for 1 h improves PL and RL efficiency due to enhanced crystallinity of the nanopowders and activation of recombination centers (Bi3+ ions). No shift in the PL peak position was observed as a function of average crystallite size. The concentration quenching was experimentally determined to have a maximum emission of around 3 mol % of the dopant. TL spectra present several peaks between 50 and 300 °C, and the total TL signal is correlated with the heat of combustion of the fuel and thus crystallinity increases. Most likely, increases in RL and TL are also due to the increase in the concentration of recombination centers. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

27. Multifunction Gd2O3:Eu nanocrystals produced by solution combustion synthesis: Structural, luminescent, and magnetic characterization.

Author

Jacobsohn, L. G., Bennett, B. L., Muenchausen, R. E., Tornga, S. C., Thompson, J. D., Ugurlu, O., Cooke, D. W., and Lima Sharma, A. L.

Subjects
*NANOCRYSTALS, *PHOTOLUMINESCENCE, *TRANSMISSION electron microscopy, *MAGNETIC properties, *PARTICLES (Nuclear physics)
Abstract

The synthesis, structural, luminescent, and magnetic properties of multifunction 8 at. % Eu-doped Gd2O3 nanocrystals were investigated. The material was synthesized by the solution combustion technique and characterized by x-ray diffraction (XRD), transmission electron microscopy, and photoluminescence and magnetization measurements. The as-prepared material presents predominant base-centered monoclinic structure with average crystallite size of 35 nm. Isothermal annealing at 1000 °C for up to 152 h induced gradual structural transition toward the body-centered cubic structure. Debye–Scherrer analysis of XRD results showed that annealing did not induce grain growth of monoclinic nanocrystals, while cubic nanocrystals reached 47 nm after annealing for 152 h. The luminescent behavior was monitored as a function of annealing time and related to the structural transformation. In particular, an inversion of the predominant photoluminescence emission line from 621.4 to 609.5 nm was observed and related to changes in the crystalline field resultant to phase transformation from cubic to monoclinic. Magnetic measurements revealed the paramagnetic nature of the material, much insensitive to the crystallographic structure. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

28. Array of cobalt nanoparticles in silica: Synthesis and effects of thermal annealing.

Author

Jacobsohn, L. G., Thompson, J. D., Misra, A., Schulze, R. K., Hundley, M. F., and Nastasi, M.

Subjects
*ANNEALING of crystals, *NANOPARTICLES, *ANISOTROPY, *PHOTOELECTRON spectroscopy, *PHYSICAL & theoretical chemistry
Abstract

The synthesis, characterization, and the effects of isochronal annealing of nearly monodispersive three-dimensional arrays of Co nanoparticles are presented. Samples were obtained by alternating electron beam evaporation of Co and SiO2 layers 0.5 and 20 nm thick, respectively, onto fused silica. Transmission electron microscopy (TEM) revealed the presence of 3.2 nm diameter Co particles with a size dispersion standard deviation of 16%. Annealing at temperatures up to 800 °C was carried out in vacuum for 5 min. Field and zero-field cooled measurements of the magnetic susceptibility monitored the effects of annealing on the magnetic behavior. Two temperature regimes were observed. One, up to 700 °C with an activation energy of 0.062 eV where no significant particle size change was observed, was tentatively related to bonding ordering within the particles. The other regime, with an activation energy of 0.67 eV, was attributed to Co diffusion and reflected particle growth as observed by TEM. These results were supported by exchange bias anisotropy and x-ray photoelectron spectroscopy measurements. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

29. The effects of ion irradiation on porous silicon photoluminescence.

Author

Jacobsohn, L. G., Bennett, B. L., Cooke, D. W., Muenchausen, R. E., and Nastasi, M.

Subjects
*IONS, *IRRADIATION, *PHOTOLUMINESCENCE, *LUMINESCENCE, *PROPERTIES of matter, *POROUS silicon
Abstract

The effects of ion irradiation on porous Si (po-Si) photoluminescence (PL) are investigated to gain insight into the emission mechanism. Po-Si was obtained by standard electrochemical etching of p-doped Si(100) and the samples were aged for several weeks to achieve stability of the PL intensity. Specimens were progressively irradiated with H+, He+, or Ne++ ions followed by PL measurements. PL spectra were obtained as a function of the displacement per atom (DPA) parameter up to a DPA level of ∼10-2, which was sufficient to nearly extinguish PL. The quenching behavior showed a strong dependence on the chemical nature of the implanted species. Within experimental error, the quenching efficiency was equivalent for He+ and Ne++ irradiations, but was considerably higher for H+ irradiation. Channeling spectrometry showed the efficiency to be correlated with the self-recovery of defects generated during irradiation. The observed PL quenching is associated with the creation of nonradiative recombination sites within the band gap, but not with Si nanostructure amorphization and/or surface oxygen removal. Significant recovery of quenched PL occurs over a period of 120 days for specimens that are stored in air, but not for samples that are stored in vacuum. These results demonstrate the importance and complexity of surface oxidation on the po-Si luminescence mechanism. [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

30. Synthesis of cobalt nanoparticles by ion implantation and effects of postimplantation annealing.

Author

Jacobsohn, L. G., Hawley, M. E., Cooke, D. W., Hundley, M. F., Thompson, J. D., Schulze, R. K., and Nastasi, M.

Subjects
*COBALT, *NANOPARTICLES, *ION implantation, *TRANSMISSION electron microscopy, *ION bombardment, *PHOTOELECTRON spectroscopy
Abstract

A study of the synthesis of Co nanoparticles by ion implantation and the effects of postimplantation annealing was carried out. Silica was implanted with 35 keV Co+ ion beams to doses ranging from 8×1015 to 1×1017 atoms/cm2. Nanoparticle size, distribution, and structure were ascertained via transmission electron microscopy measurements, which reveal the presence of spherical nanoparticles in both as-implanted and annealed samples. X-ray photoelectron spectroscopy show the chemical state of the nanoparticles in both as-implanted and annealed samples to be metallic. Temperature-dependent field-cooled and zero-field-cooled, susceptibility measurements indicated superparamagnetic behavior, which is analyzed by accounting for the size dispersion of the nanoparticles. Results showed that the magnetic properties of the specimen can be tailored by implantation conditions. Annealing in vacuum at 900 °C for up to 10 h leads to an increase of the average nanoparticle size and a broader size distribution. Mie scattering and magnetic force microscopy measurements provide evidence of a strong interaction among the nanoparticles in the annealed samples. The feasibility of obtaining small-dispersion size-controlled synthesis of Co nanoparticles at room temperature is illustrated. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

31. The role of the chemical nature of implanted species on quenching and recovery of photoluminescence in ion-irradiated porous silicon.

Author

Jacobsohn, L. G., Cooke, D. W., Bennett, B. L., Muenchausen, R. E., and Nastasi, M.

Subjects
*IRRADIATION, *PHOTOLUMINESCENCE, *CHANNELING (Physics), *SILICON, *HYDROGEN ions, *HELIUM ions, *SPECTROMETRY, *SPECTRUM analysis
Abstract

The effects of ion irradiation on porous Si (po-Si) photoluminescence (PL) have been investigated. Specimens were progressively irradiated with H+ and He+ ions followed by PL measurements. After the final irradiation, which resulted in total PL quenching, PL recovery was monitored for more than 200 days. The behavior of both PL quenching and recovery was correlated to the amount of retained irradiation-induced damage, determined by channeling spectrometry measurements, and to the chemical nature of the implanted species. Quenching was attributed to the generation of defects that create nonradiative states within the gap, while recovery was attributed to the passivation of these defects by atmospheric exposure. H+ irradiation is approximately five times more efficient in quenching PL and leads to approximately four times lower recovery rate than He+ irradiation. This behavior is attributed to the formation of stable H-defect complexes. [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

38. Crescer com paralisia cerebral

Author

Alves, A, Cadete, A, Figueiredo, H, Gabriel, C, Jacobsohn, L, Oliveira, A, Patinha, D, and Valério, P

Subjects
Criança, Paralisia cerebral
Published
2004

42. Positron annihilation spectroscopy of sputtered boron carbide films

Author

Jacobsohn, L. G., Nastasi, M., Daemen, L. L., Jenei, Zsolt, Asoka-Kumar, P., Jacobsohn, L. G., Nastasi, M., Daemen, L. L., Jenei, Zsolt, and Asoka-Kumar, P.

Abstract

Positron annihilation spectroscopy (PAS) was carried out on boron carbide films deposited by sputtering and the results correlated to the bombardment conditions during film growth. Films were deposited with substrate bias voltages in the range of 0 to −200 V with a working pressure of 5 mTorr of Ar. Films deposited with bias voltages from −100 to −200 V present the same type of defect and the defect concentration increased linearly with the bias voltage. This defect was ascribed to vacancies in agreement with Monte Carlo simulations of Ar+ bombardment of boron carbide. On the other hand, films deposited with 0 V bias presented a higher S parameter values, whose origin was tentatively attributed to a relatively more open nanosized columnar structure, as suggested by the structure zone model. Annealing up to 800 °C for 30 min did not change the defect content.

Published
2005
Full Text
View/download PDF

44. Role of intericosahedral chains on hardness of sputtered boron carbide films

Author

Jacobsohn, L. G, Averitt, R. D., Wetteland, C. J., Schulze, R. K., Nastasi, M., Daemen, L. L., Jenei, Zsolt, Asoka-Kumar, P., Jacobsohn, L. G, Averitt, R. D., Wetteland, C. J., Schulze, R. K., Nastasi, M., Daemen, L. L., Jenei, Zsolt, and Asoka-Kumar, P.

Abstract

The relationship between the structure and mechanical properties of sputter-deposited boron carbide films was investigated. Changes in the structure induced by annealing were characterized in terms of chemical composition, chemical bonding, and concentrations of defects and trapped impurities. The creation of intericosahedral chains for higher annealing temperatures was revealed by infrared and Raman measurements, and the intensity of the infrared band at 1500 cm–1 was found to be related to the hardness. The presence of residual trapped Ar atoms and of open-volume defects is insensitive to relatively high annealing temperatures and does not influence the recovery of the hardness. Our results suggest postdeposition annealing as a pathway to enhance the mechanical properties of boron carbide films.

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results